The partners will evaluate circulating tumor cell-based biomarker panels as potential new tests for use on Ikonisys' Ikoniscope fluorescence microscopy system.
The team will combine Akoya's Vectra Polaris system with Precision for Medicine's Apostream tool to validate companion diagnostics and assess drug efficacy.
The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.
The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.
LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.
